Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Endo Pharmaceuticals |
---|---|
Information provided by: | Endo Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00262678 |
The purpose of this study is to determine the effectiveness and safety of sublingual fentanyl tablets in relieving breakthrough pain in cancer patients.
Condition | Intervention | Phase |
---|---|---|
Pain Cancer |
Drug: EN3267 |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Safety/Efficacy Study |
Official Title: | A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of EN3267 for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients. |
Ages Eligible for Study: | 17 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | EN3267-005 |
Study First Received: | December 6, 2005 |
Last Updated: | September 12, 2007 |
ClinicalTrials.gov Identifier: | NCT00262678 |
Health Authority: | United States: Food and Drug Administration |
Fentanyl Pain |